• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Introduction to Tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate (CAS No. 2172112-40-0)

Tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate, identified by the Chemical Abstracts Service Number (CAS No.) 2172112-40-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This spirocyclic azapeptide derivative exhibits a unique structural framework, combining a spirocyclic core with azapeptide functionalities, which makes it a promising candidate for various biochemical applications.

The molecular structure of tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate features a spirocyclic connection between a six-membered and a five-membered ring, with an azapeptide moiety integrated into the system. This configuration imparts distinct stereochemical properties and reactivity patterns, making it an intriguing subject for synthetic and mechanistic studies. The presence of a tert-butyl group at the carboxyl position enhances the compound's stability and solubility, facilitating its use in both in vitro and in vivo experimental settings.

Recent advancements in drug discovery have highlighted the potential of spirocyclic compounds due to their ability to mimic natural product scaffolds and exhibit favorable pharmacokinetic profiles. The 6-ethyl substituent in the molecule further modulates its electronic properties, influencing its interactions with biological targets. This compound has been explored as a lead structure in the development of novel therapeutic agents, particularly in the realm of enzyme inhibition and receptor binding studies.

In the context of medicinal chemistry, 2-azaspiro4.5decane derivatives have shown promise as scaffolds for designing molecules with enhanced binding affinity and selectivity. The 4-carboxylate functionality provides a site for further chemical modifications, enabling the synthesis of analogs with tailored biological activities. Researchers have utilized computational methods to predict the binding modes of this compound with various protein targets, suggesting its potential as an inhibitor of key enzymes involved in metabolic pathways.

One of the most compelling aspects of tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate is its versatility in synthetic chemistry. The spirocyclic core allows for diverse functionalization strategies, making it a valuable building block for constructing more complex molecules. For instance, recent studies have demonstrated its utility in generating libraries of derivatives for high-throughput screening (HTS) campaigns aimed at identifying novel bioactive compounds.

The pharmacological profile of this compound has been preliminarily assessed through both computational modeling and experimental validation. Initial studies indicate that it interacts with specific binding sites on target proteins, modulating their activity in ways that could be therapeutically relevant. The tert-butyl group, in particular, has been shown to enhance binding affinity by stabilizing key interactions through steric hindrance and hydrophobic effects.

From a synthetic perspective, the preparation of tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate involves multi-step organic transformations, including spirocyclization reactions and peptide coupling techniques. Advances in synthetic methodologies have enabled more efficient and scalable production processes, making it feasible to conduct large-scale screenings and derivatization efforts. The compound's stability under various storage conditions further enhances its practicality for industrial applications.

The integration of tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate into drug development pipelines is still in its early stages, but preliminary results are encouraging. Researchers are exploring its potential in treating conditions related to enzyme dysregulation and metabolic disorders. The compound's unique structural features offer a rationale for its selective interaction with biological targets, minimizing off-target effects—a critical consideration in modern drug design.

Future research directions may focus on optimizing the synthesis of this compound to improve yield and reduce costs, as well as investigating its pharmacokinetic properties to ensure suitability for clinical translation. Additionally, exploring its role in combination therapies could unlock new therapeutic strategies by leveraging synergistic effects with other bioactive molecules.

In summary, tert-butyl 6-ethyl-2-azaspiro4.5decane-4-carboxylate (CAS No. 2172112-40-0) represents a significant advancement in pharmaceutical chemistry, offering a structurally unique scaffold with promising biological activities. Its versatility in synthetic chemistry and favorable pharmacological profile make it a valuable asset in the quest for novel therapeutic agents.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)